Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Erez-Israeli"

3 News Found

Dr. Reddy's Laboratories to acquire Mayne Pharma’s U.S. generic prescription product portfolio
News | March 01, 2023

Dr. Reddy's Laboratories to acquire Mayne Pharma’s U.S. generic prescription product portfolio

The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.

Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent
Drug Approval | September 04, 2021

Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent

In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.

Dr. Reddy's Laboratories signs asset purchase agreement with BioDelivery Sciences
News | August 05, 2021

Dr. Reddy's Laboratories signs asset purchase agreement with BioDelivery Sciences

Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing

Latest Stories

Gland Pharma appoints Satnam Singh Loomba as COO

Gland Pharma receives approval for cetrorelix acetate for injection

AstraZeneca’s Truqap plus Faslodex recommended for approval in the EU by CHMP for cancer treatment

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
Vinod Paremal President & MD, Evonik, India Region

Packaging